Source Health Economics
  • Home
  • Services
    • Economic Modelling & Data Analysis
    • Evidence Generation
    • Market Access and Value Communication
    • Health Technology Assessment
    • Training
  • Team
  • Insights
  • Join us
  • Get in touch
Select Page
What are the implications of joint clinical assessment (JCA) on systematic reviews?

What are the implications of joint clinical assessment (JCA) on systematic reviews?

by acaballero | Aug 8, 2024 | Industry insights

Written by Sneha Bhadti, David Pritchett, & Susan O’Connell   The implementation of the European Union (EU) joint clinical assessment (JCA) process is fast approaching. In January 2025, the JCA will be rolled out for new oncology and orphan medications....
The European Union Joint Clinical Assessment (EU JCA) – an overview

The European Union Joint Clinical Assessment (EU JCA) – an overview

by Rachel Montague | Jul 15, 2024 | Industry insights

Written by Susan O’Connell, Louise Crathorne, & Sneha Bhadti   In the realm of healthcare innovation, the European Union (EU) is paving the way with the Joint Clinical Assessment (JCA) process In this background article, Source aims to highlight some of the...
Quality assessment in single-arm trials: insights for systematic reviews

Quality assessment in single-arm trials: insights for systematic reviews

by acaballero | Apr 9, 2024 | Industry insights, Uncategorised

Written by Hannah Shapiro   Quality assessment in single-arm trials Quality assessment is a vital aspect of conducting a thorough systematic literature review (SLR), as the validity of the conclusions of the review depends on the reliability of the included...
A ‘NICE’ Innovation: The Proportionate Approach

A ‘NICE’ Innovation: The Proportionate Approach

by acaballero | Mar 25, 2024 | Industry insights

Written by Kiera Lander, Assistant Project Manager   The National Institute for Health and Care Excellence (NICE) has long been at the forefront of health technology assessment (HTA), ensuring that patients have access to innovative, efficacious medicines....
Out of the frying pan and into the fire: Moving to a market access consultancy company

Out of the frying pan and into the fire: Moving to a market access consultancy company

by acaballero | Mar 18, 2024 | Industry insights

Written by Brian O’Toole, HTA Writing Lead   Last year I changed jobs. It was a major life decision that took time to make as it meant leaving the comfort and familiarity of academia for the hustle and bustle of a market access consultancy. For the past...
AI-enabled triage in the NHS: an economic analysis

AI-enabled triage in the NHS: an economic analysis

by acaballero | Mar 13, 2024 | Industry insights

Written by Mark Pennington, Consultant Health Economist   With the UK’s National Health Service (NHS) facing an unprecedented patient demand for healthcare, there is increasing interest in artificial intelligence (AI) and how it can support healthcare diagnoses....
« Older Entries

London

91 Wimpole Street
London
W1G 0EF

Oxford

Floor 2, 226 Banbury Road, Summertown, Oxford, OX2 7BY
+44 (0) 1865 920 567

Connect

Connect with us on LinkedIn

  • © Source Market Access Ltd t/a Source Health Economics
  • Cookies
  • Website by Herd

Company registration number: 10284529 | VAT number: GB248 0293 06

Cookies Policy

Our Website uses cookies to improve your experience. Please visit our Cookies page for more information about cookies and how we use them.

Close